iiinova — where your digital self keeps evolving

Scribe Therapeutics @scribetx.bsky.social · 30/06/2026

Next Tuesday, we’re presenting at #GENESRC, the Genome Engineering: Research and Applications conference hosted by @faseborg.bsky.social. Details below on our session about increasing the potency of CasX-based editors to enable safer, more effective CRISPR-based therapeutics. #FASEB #CRISPR

021

Scribe Therapeutics @scribetx.bsky.social · 25/06/2026

Dr. Jennifer Doudna, Nobel laureate and Scribe co-founder, shares her vision for the future of gene editing with Bloomberg Originals host Emily Chang. Full video and article links in thread 🧵

100

Scribe Therapeutics @scribetx.bsky.social · 23/06/2026

🧬 @economist.com breaks down epigenetic medicine, the next frontier for CRISPR-based therapies: → How #EpigeneticEditing works → Potential safety advantages → How genes like PCSK9 that Scribe is focused on could be targeted to reduce LDL cholesterol and cardiovascular risk

100

Scribe Therapeutics @scribetx.bsky.social · 19/06/2026

This Juneteenth, we invited our Alameda neighbor, Sips Global Tea, to share their knowledge and collection of global teas sourced from Africa, Asia, South America, and Europe with our team. Thanks for leading us through the craft and culture of tea blending for a day of learning and community 🍵

000

Scribe Therapeutics @scribetx.bsky.social · 18/06/2026

We’re excited to share that @cirmnews.bsky.social has awarded Scribe more than $25 million through its Preclinical Development Program to accelerate the advancement of two preclinical programs targeting cardiovascular and metabolic disease. Press release in thread 📣

100

Scribe Therapeutics @scribetx.bsky.social · 17/06/2026

At #BIO2026, meet the BD team behind Scribe’s collaborations with leading pharma companies like Lilly and Sanofi. Set up a meeting using the BIO portal to learn how partnerships broaden and accelerate the impact of our engineered #CRISPR tech 👇 partner.bio.org/conference/8...

000

Scribe Therapeutics @scribetx.bsky.social · 12/06/2026

Our go-to recipe for a team brunch? Good food and even better company. At Scribe, we have it down to a science. 🧑‍🍳

000

Scribe Therapeutics @scribetx.bsky.social · 10/06/2026

In Precision Medicine Online, read about our first clinical trial for STX-1150, our novel, in vivo therapy designed to epigenetically silence PCSK9 and deliver sustained LDL-C reduction after a single dose – without permanently altering DNA. 📖 www.precisionmedicineonline.com/regulatory-n...

000

Scribe Therapeutics @scribetx.bsky.social · 28/05/2026

At #EASCongress2026, we presented late-breaking preclinical data on our lead cardiometabolic program STX-1150. These data support STX-1150 as a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose. Study highlights below ⬇️

100

Scribe Therapeutics @scribetx.bsky.social · 25/05/2026

#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @benjaminloakes.bsky.social will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic. Thanks @eassociety.bsky.social for featuring it!

010

Scribe Therapeutics @scribetx.bsky.social · 22/05/2026

In the Herald Sun, Dr. Stephen Nicholls of Victorian Heart Institute, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️

100

Scribe Therapeutics @scribetx.bsky.social · 21/05/2026

Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s Therapeutic Goods Administration to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease. Details🧵

110

Scribe Therapeutics @scribetx.bsky.social · 18/05/2026

At #ASGCT2026, we presented preclinical data highlighting the latest advances across our engineered #CRISPR technologies for epigenetic silencing and gene editing. Highlights of our three oral presentations below and in thread 🧵 www.businesswire.com/news/home/20...

110

Scribe Therapeutics @scribetx.bsky.social · 14/05/2026

Two #ASGCT26 oral presentations tomorrow! 🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency 🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors

000

Scribe Therapeutics @scribetx.bsky.social · 11/05/2026

We’re kicking off #ASGCT2026 today with a workshop by co-founder & VP of External Innovation Brett Staahl. Details below & more to come at @asgct.bsky.social later this week! 🔹Engineering CasX from clay to clinic: lessons in precision, potency, and translatability 🕒 May 11 at 3:07 pm ET

100

Scribe Therapeutics @scribetx.bsky.social · 25/04/2026

Happy #DNADay26! Today, we celebrate the ongoing innovations in genetics and epigenetics that are shaping the future of human health. 🧬 At Scribe, we're committed to bringing novel #CRISPR-based genetic medicines to patients in need. Learn more at scribetx.com.

032

Scribe Therapeutics @scribetx.bsky.social · 07/04/2026

This #WorldHealthDay, we’re recognizing the importance of scientific progress in improving lives. At Scribe, that mission continues to guide our work every day to advance novel #CRISPR-based genetic medicines for patients, starting with those with cardiovascular disease.

000

Scribe Therapeutics @scribetx.bsky.social · 31/03/2026

What does it take to build & lead a biotech today? Some valuable insights from our CBO Svetlana Lucas at the BioPioneers #WomensHistoryMonth event: ✅ Execute with utmost focus and discipline. 📈 Get comfortable being uncomfortable. 💡 Emotional intelligence is a differentiator.

000

Scribe Therapeutics @scribetx.bsky.social · 27/03/2026

To celebrate the start of spring, our team traded lab coats 🥼 for garden gloves for an afternoon of planting, propagating, and building out a community herb garden. 🌱 A fun way to welcome the season and spend time together outside the lab!

000

Scribe Therapeutics @scribetx.bsky.social · 24/03/2026

Today is #LpaAwarenessDay. Do you know your Lp(a)? Fewer than 1% of individuals with elevated levels of Lp(a) are aware of it. Now, a new @americanheart.bsky.social and @accintouch.bsky.social guideline recommends universal Lp(a) screening at least once in a lifetime. More in 🧵 #KnowLpa

110

Scribe Therapeutics @scribetx.bsky.social · 20/03/2026

❤️‍🩹 New guideline from @accintouch.bsky.social, @americanheart.bsky.social, and other leading medical organizations reflects a key shift in cardiovascular care: → Earlier LDL-C testing → Targeting lower LDL-C levels based on risk → Greater focus on prevention over time More in our thread 👇

100

Scribe Therapeutics @scribetx.bsky.social · 17/03/2026

Celebrate #WomensHistoryMonth this Thursday with a powerhouse panel of C-suite leaders, including our Chief Business Officer Svetlana Lucas. Get your ticket to the BioPioneers event for insights on the future of biotech: luma.com/583ce9z8 #WomenInSTEM #WomenInScience

000

Scribe Therapeutics @scribetx.bsky.social · 13/03/2026

Scribe was created to expand #CRISPR's use beyond rare diseases, said CEO @benjaminloakes.bsky.social in an interview with @precmedonline.bsky.social. Read about our progress in bringing our lead therapy for cardiovascular disease to the clinic 👉 www.precisionmedicineonline.com/business-new...

010

Scribe Therapeutics @scribetx.bsky.social · 10/03/2026

Join us at today's @keystonesymposia.bsky.social Precision Genome Engineering conference, where we're presenting our latest #EpigeneticEditing advances at 7:30pm. 📣 ADDing a Lock to Epigenome Editing: DNMT3A Allostery Enhances Specificity and Potency of #CRISPR-CasX-based Epigenetic Repressors

031

Scribe Therapeutics @scribetx.bsky.social · 07/03/2026

For this International Women's Day, our Scribe team came together to assemble care packages for women and communities in need. Thank you to everyone who showed up to #GiveToGain in support of women everywhere. #InternationalWomensDay #WomenInSTEM

111

Scribe Therapeutics @scribetx.bsky.social · 03/03/2026

Hypercholesterolemia is a major driver of cardiovascular disease. This BioWorld article covers our work to advance STX-1150 – designed to durably lower LDL-C via epigenetic silencing of PCSK9 – into the clinic and meaningfully change how #CVD is treated. www.bioworld.com/articles/728...

bioworld.com

Scribe eyes clinic with STX-1150 for hypercholesterolemia

Scribe Therapeutics Inc. is aiming to advance STX-1150, its lead product candidate for the treatment of hypercholesterolemia, into the clinic around the middle of this year. Hypercholesterolemia is a ...

100

Scribe Therapeutics @scribetx.bsky.social · 27/02/2026

Read the latest in @longevitytech.bsky.social about our second success milestone with @elilillyandcompany.bsky.social and the demonstration of “steady, disciplined progress toward a future where genetic medicine plays a central role in how we manage aging and chronic disease."

longevity.technology

Gene editing partnership reaches new in vivo success

A second milestone for Scribe and Lilly highlights growing confidence in CRISPR as a tool for longer, healthier lives.

000

Scribe Therapeutics @scribetx.bsky.social · 24/02/2026

At Scribe, we believe the standard of cardiovascular care today needs a paradigm shift. Cardiovascular Business spotlights our development of novel #CRISPR-based medicines that target the key lipid drivers of ASCVD – check out the article preview and link below. 👇

100

Scribe Therapeutics @scribetx.bsky.social · 20/02/2026

Dr. Jennifer Doudna, Nobel laureate & Scribe co-founder, is one of America’s greatest innovators. Our CEO and co-founder @benjaminloakes.bsky.social spoke with @forbes.com about her unmatched impact on science and medicine. Check out Dr. Doudna’s Forbes 250 profile in the links below 👇

110

Scribe Therapeutics @scribetx.bsky.social · 17/02/2026

We achieved a second success milestone with @elilillyandcompany.bsky.social in our collaboration to advance in vivo #CRISPR-based therapies for neurological and neuromuscular disorders. Progress like this matters because patients cannot wait. More details in thread 🧵 #CRISPR #GeneEditing

140

Scribe Therapeutics @scribetx.bsky.social · 13/02/2026

Our thanks to BiopharmaTrend for highlighting our newest preprint! We detail the engineering behind our ELXR epigenetic silencing tech – including a new control layer for the CasX-based epigenetic silencer. The result: Improved precision for CRISPR-based therapeutics. Details ⬇️

100

Scribe Therapeutics @scribetx.bsky.social · 11/02/2026

Can #CRISPR genetic medicine solve cardiovascular disease? We’re advancing STX-1150 into first-in-human clinical trials to target LDL-C, one of the biggest drivers of heart disease, and reduce ASCVD risk without permanently changing the DNA. @longevitytech.bsky.social article below 👇

100

Scribe Therapeutics @scribetx.bsky.social · 07/02/2026

We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️‍🩹 Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart... #HeartDisease #OurHearts #HeartMonth

000

Scribe Therapeutics @scribetx.bsky.social · 04/02/2026

💡 During #AmericanHeartMonth, check out a thoughtful interview Scribe’s co-founder Jennifer Doudna recorded with Core Memory founder @ashleevance.bsky.social – highlighting how #CRISPR could shift current cardiometabolic disease treatment from symptom management to prevention. Links ⬇️

100

Scribe Therapeutics @scribetx.bsky.social · 30/01/2026

How do we engineer #CRISPR genetic medicines with the potency, specificity, and durability to treat not only rare disease, but also highly prevalent conditions? Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧

110

Scribe Therapeutics @scribetx.bsky.social · 27/01/2026

As #AmericanHeartMonth approaches, we're preparing to advance a new therapy for cardiovascular disease. STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics. More in @endpts.com 👇

100

Scribe Therapeutics @scribetx.bsky.social · 23/01/2026

Another successful JPM is in the books 📕 From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.

100

Scribe Therapeutics @scribetx.bsky.social · 20/01/2026

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

110

Scribe Therapeutics @scribetx.bsky.social · 14/01/2026

Happening TODAY at #JPM2026! Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT). #JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD

021

Scribe Therapeutics @scribetx.bsky.social · 09/01/2026

Kick off JPM Week with us this Sunday! Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more. Details below 🧬👇

000

Scribe Therapeutics @scribetx.bsky.social · 07/01/2026

Coming up next week at #JPM2026: Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT! Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD

210

Scribe Therapeutics @scribetx.bsky.social · 01/01/2026

Wishing everyone a Happy New Year!

000

Scribe Therapeutics @scribetx.bsky.social · 23/12/2025

Check out this Singularity Hub article about Scribe's breakthrough #AHA25 data on our #CRISPR epigenetic and gene editing medicines for heart disease. Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇 singularityhub.com/2025/11/27/c...

singularityhub.com

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

A range of CRISPR gene therapies are taking aim at chronically high cholesterol, reducing the risk of heart disease.

000

Scribe Therapeutics @scribetx.bsky.social · 19/12/2025

ICYMI, our latest data is out in Fierce Biotech. Read about our lead candidate – epigenetic silencing therapy STX-1150 – and #CRISPR gene editors STX-1200 and STX-1400, designed to safely and durably address the main lipid drivers of heart disease. Article by @megadarren.bsky.social.

fiercebiotech.com

Scribe eyes clinic after CRISPR candidates lower lipids in animals

Genetic-medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three programs, all of which were able to reduce cardiovascular risk factors in | ...

011

Scribe Therapeutics @scribetx.bsky.social · 17/12/2025

Could a single treatment lower heart disease risk by up to 90%? At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.

110

Scribe Therapeutics @scribetx.bsky.social · 15/12/2025

Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference. Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026. #JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD

110

Scribe Therapeutics @scribetx.bsky.social · 04/12/2025

Thanks to Drug Discovery News for the great coverage featuring Scribe CEO @benjaminloakes.bsky.social's thoughts on the current state and future potential of AI-assisted CRISPR technologies. Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...

drugdiscoverynews.com

Can AI take the guesswork out of CRISPR?

New AI tools promise to speed up and simplify CRISPR experiments, but their real-world impact is still being tested.

000

Scribe Therapeutics @scribetx.bsky.social · 01/12/2025

This week, Scribe’s Computational Genomics & Data Science Team is at @awscloud.bsky.social re:Invent 2025 for the AWS AI League Championship Finals, competing against top AI innovators nationwide. Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!

100

Scribe Therapeutics @scribetx.bsky.social · 26/11/2025

As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful. Happy Thanksgiving! 🦃

000